Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10816335,ED50,The ED50 value of a nimesulide-piperine combination in writhing test was calculated to be significantly lower (1.5 mg kg(-1)) as compared to (11.2 mg kg(-1)) of nimesulide alone.,"Comparative anti-nociceptive, anti-inflammatory and toxicity profile of nimesulide vs nimesulide and piperine combination. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10816335/),[mg] / [kg],1.5,4574,DB04743,Nimesulide
,10816335,ED50,The ED50 value of a nimesulide-piperine combination in writhing test was calculated to be significantly lower (1.5 mg kg(-1)) as compared to (11.2 mg kg(-1)) of nimesulide alone.,"Comparative anti-nociceptive, anti-inflammatory and toxicity profile of nimesulide vs nimesulide and piperine combination. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10816335/),[mg] / [kg],11.2,4575,DB04743,Nimesulide
,11348485,plasma clearance,"After i.v. administration, the plasma clearance was 15.3 +/- 4.2 mL/kg/h, the steady-state volume of distribution was low (0.18 +/- 0.011 L/kg) and the elimination half-life was 8.5 +/- 2.1 h.",Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348485/),[ml] / [h·kg],15.3,9054,DB04743,Nimesulide
,11348485,steady-state volume of distribution,"After i.v. administration, the plasma clearance was 15.3 +/- 4.2 mL/kg/h, the steady-state volume of distribution was low (0.18 +/- 0.011 L/kg) and the elimination half-life was 8.5 +/- 2.1 h.",Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348485/),[l] / [kg],0.18,9055,DB04743,Nimesulide
,11348485,elimination half-life,"After i.v. administration, the plasma clearance was 15.3 +/- 4.2 mL/kg/h, the steady-state volume of distribution was low (0.18 +/- 0.011 L/kg) and the elimination half-life was 8.5 +/- 2.1 h.",Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348485/),h,8.5,9056,DB04743,Nimesulide
,11348485,terminal half-life,"After i.m. administration, the terminal half-life was 14.0 +/- 5.3 h indicating a slow process of absorption with a maximum plasma concentration (6.1 +/- 1.5 microg/mL) at 10.9 +/- 2.1 h postadministration and the systemic bioavailability was 69 +/- 22%.",Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348485/),h,14.0,9057,DB04743,Nimesulide
,11348485,maximum plasma concentration,"After i.m. administration, the terminal half-life was 14.0 +/- 5.3 h indicating a slow process of absorption with a maximum plasma concentration (6.1 +/- 1.5 microg/mL) at 10.9 +/- 2.1 h postadministration and the systemic bioavailability was 69 +/- 22%.",Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348485/),[μg] / [ml],6.1,9058,DB04743,Nimesulide
,11348485,systemic bioavailability,"After i.m. administration, the terminal half-life was 14.0 +/- 5.3 h indicating a slow process of absorption with a maximum plasma concentration (6.1 +/- 1.5 microg/mL) at 10.9 +/- 2.1 h postadministration and the systemic bioavailability was 69 +/- 22%.",Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348485/),%,69,9059,DB04743,Nimesulide
,11348485,maximal plasma concentration,"After oral administration in fasted dogs, the maximal plasma concentration (10.1 +/- 2.7 microg/mL) was observed 6.1 +/- 1.6 h after drug administration, the plasma half-life was 6.2 +/- 1.9 h and the mean bioavailability was 47 +/- 12%.",Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348485/),[μg] / [ml],10.1,9060,DB04743,Nimesulide
,11348485,plasma half-life,"After oral administration in fasted dogs, the maximal plasma concentration (10.1 +/- 2.7 microg/mL) was observed 6.1 +/- 1.6 h after drug administration, the plasma half-life was 6.2 +/- 1.9 h and the mean bioavailability was 47 +/- 12%.",Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348485/),h,6.2,9061,DB04743,Nimesulide
,11348485,bioavailability,"After oral administration in fasted dogs, the maximal plasma concentration (10.1 +/- 2.7 microg/mL) was observed 6.1 +/- 1.6 h after drug administration, the plasma half-life was 6.2 +/- 1.9 h and the mean bioavailability was 47 +/- 12%.",Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348485/),%,47,9062,DB04743,Nimesulide
,11348485,plasma concentration,"After daily oral administrations for 5 days, the average plasma concentration during the fifth dosage interval was 8.1 +/- 2.9 microg/mL and the overall bioavailability was 58 +/- 16%.",Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348485/),[μg] / [ml],8.1,9063,DB04743,Nimesulide
,11348485,overall bioavailability,"After daily oral administrations for 5 days, the average plasma concentration during the fifth dosage interval was 8.1 +/- 2.9 microg/mL and the overall bioavailability was 58 +/- 16%.",Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348485/),%,58,9064,DB04743,Nimesulide
,11348485,accumulation ratio,The mean accumulation ratio was 1.27 +/- 0.4.,Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348485/),,1.27,9065,DB04743,Nimesulide
,11348485,inhibitory concentration (IC50),The inhibitory concentration (IC50) for inhibition of COX-2 and COX-1 were 1.6 +/- 0.4 microM (0.49 +/- 0.12 microg/mL) and 20.3 +/- 2.8 microM (6.3 +/- 0.86 microg/mL) giving a nimesulide COX-1/COX-2 ratio of 12.99 +/- 3.41.,Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348485/),μM,1.6,9066,DB04743,Nimesulide
,11348485,inhibitory concentration (IC50),The inhibitory concentration (IC50) for inhibition of COX-2 and COX-1 were 1.6 +/- 0.4 microM (0.49 +/- 0.12 microg/mL) and 20.3 +/- 2.8 microM (6.3 +/- 0.86 microg/mL) giving a nimesulide COX-1/COX-2 ratio of 12.99 +/- 3.41.,Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348485/),[μg] / [ml],0.49,9067,DB04743,Nimesulide
,11348485,inhibitory concentration (IC50),The inhibitory concentration (IC50) for inhibition of COX-2 and COX-1 were 1.6 +/- 0.4 microM (0.49 +/- 0.12 microg/mL) and 20.3 +/- 2.8 microM (6.3 +/- 0.86 microg/mL) giving a nimesulide COX-1/COX-2 ratio of 12.99 +/- 3.41.,Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348485/),μM,20.3,9068,DB04743,Nimesulide
,11348485,inhibitory concentration (IC50),The inhibitory concentration (IC50) for inhibition of COX-2 and COX-1 were 1.6 +/- 0.4 microM (0.49 +/- 0.12 microg/mL) and 20.3 +/- 2.8 microM (6.3 +/- 0.86 microg/mL) giving a nimesulide COX-1/COX-2 ratio of 12.99 +/- 3.41.,Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348485/),[μg] / [ml],6.3,9069,DB04743,Nimesulide
,11348485,COX-1/COX-2 ratio,The inhibitory concentration (IC50) for inhibition of COX-2 and COX-1 were 1.6 +/- 0.4 microM (0.49 +/- 0.12 microg/mL) and 20.3 +/- 2.8 microM (6.3 +/- 0.86 microg/mL) giving a nimesulide COX-1/COX-2 ratio of 12.99 +/- 3.41.,Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348485/),,12.99,9070,DB04743,Nimesulide
,2031992,tissue/plasma ratio,The highest tissue/plasma ratio (0.5) was also found at that time.,Distribution of oral nimesulide in female genital tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031992/),,0.5,17723,DB04743,Nimesulide
,9812177,peak concentrations (Cmax),Mean peak concentrations (Cmax) of 2.86 to 6.50 mg/L were achieved within 1.22 to 2.75 hours of administration.,Clinical pharmacokinetics of nimesulide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[mg] / [l],2.86 to 6.50,18714,DB04743,Nimesulide
,9812177,bioavailability,"When nimesulide was administered in the suppository form, the Cmax was lower and occurred later than after oral administration; the bioavailability of nimesulide via suppository ranged from 54 to 64%, relative to that of orally administered formulations.",Clinical pharmacokinetics of nimesulide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),%,54 to 64,18715,DB04743,Nimesulide
,9812177,apparent volume of distribution,Nimesulide is rapidly distributed and has an apparent volume of distribution ranging between 0.18 and 0.39 L/kg.,Clinical pharmacokinetics of nimesulide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[l] / [kg],0.18 and 0.39,18716,DB04743,Nimesulide
,9812177,unbound fraction,It is extensively bound to albumin; the unbound fraction in plasma was 1%.,Clinical pharmacokinetics of nimesulide. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),%,1,18717,DB04743,Nimesulide
,9812177,terminal elimination half-life,The estimated mean terminal elimination half-life varied from 1.80 to 4.73 hours.,Clinical pharmacokinetics of nimesulide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),h,1.80 to 4.73,18718,DB04743,Nimesulide
,9812177,total plasma clearance,"The total plasma clearance of nimesulide, was 31.02 to 106.16 ml/h/kg, reflecting almost exclusive metabolic clearance.",Clinical pharmacokinetics of nimesulide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[ml] / [h·kg],31.02 to 106.16,18719,DB04743,Nimesulide
,9812177,extraction ratio,"The drug has a low extraction ratio, close to 0.1.",Clinical pharmacokinetics of nimesulide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),,0.1,18720,DB04743,Nimesulide
,10072704,tmax,Peak anti-inflammatory effects with nimesulide were observed between 2 and 3 h post-treatment which correlates well with the tmax of 115 min.,Anti-inflammatory activity and pharmacokinetic profile of a new parenteral formulation of nimesulide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072704/),min,115,39988,DB04743,Nimesulide
,10072704,Peak plasma concentration (Cmax),Peak plasma concentration (Cmax) was 23 microgram ml-1 while t1/2 was derived as 4.2 h.,Anti-inflammatory activity and pharmacokinetic profile of a new parenteral formulation of nimesulide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072704/),[μg] / [ml],23,39989,DB04743,Nimesulide
,10072704,t1/2,Peak plasma concentration (Cmax) was 23 microgram ml-1 while t1/2 was derived as 4.2 h.,Anti-inflammatory activity and pharmacokinetic profile of a new parenteral formulation of nimesulide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072704/),h,4.2,39990,DB04743,Nimesulide
,10072704,Area Under Curve (AUC(0-6 h)),Area Under Curve (AUC(0-6 h)) was calculated as 83. 31 microgram ml-1 h-1.,Anti-inflammatory activity and pharmacokinetic profile of a new parenteral formulation of nimesulide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072704/),[μg] / [h·ml],83. 31,39991,DB04743,Nimesulide
,15081941,retention time,The retention time was 4.5 min.,Rapid determination of nimesulide in rabbit aqueous humor by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081941/),min,4.5,52359,DB04743,Nimesulide
over,15081941,recovery,The recovery was over 90%.,Rapid determination of nimesulide in rabbit aqueous humor by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081941/),%,90,52360,DB04743,Nimesulide
greater,21901977,extraction recovery,The mean extraction recovery was greater than 41.2%.,Hollow fiber liquid-phase microextraction for the determination of nimesulide in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21901977/),%,41.2,52714,DB04743,Nimesulide
,7506156,maximum nimesulide concentration,"In a pharmacokinetic study of healthy volunteers who received oral nimesulide 100mg as a single dose, the mean maximum nimesulide concentration (0.58 +/- 0.13 mg/L) in seminal fluid was achieved after 2 hours while the maximum seminal fluid: blood plasma ratio 0.32 +/- 0.02 was observed after 4 hours.",Treatment of abacterial prostato-vesiculitis with nimesulide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506156/),[mg] / [l],0.58,55703,DB04743,Nimesulide
,7506156,maximum seminal fluid: blood plasma ratio,"In a pharmacokinetic study of healthy volunteers who received oral nimesulide 100mg as a single dose, the mean maximum nimesulide concentration (0.58 +/- 0.13 mg/L) in seminal fluid was achieved after 2 hours while the maximum seminal fluid: blood plasma ratio 0.32 +/- 0.02 was observed after 4 hours.",Treatment of abacterial prostato-vesiculitis with nimesulide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506156/),,0.32,55704,DB04743,Nimesulide
,7506151,peak plasma: tissue ratio,"With a single oral dose of 100mg, nimesulide is evenly distributed in female genital tissues (uterine fundus and cervix, oviduct and ovaries), reaching peak concentrations and peak plasma: tissue ratio (0.5) 3 hours after administration.",Nimesulide in dysmenorrhoea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506151/),,0.5,55805,DB04743,Nimesulide
,19544676,Cmax,"Nimesulide whole blood levels were determined by HPLC and the pharmacokinetic parameters; Cmax 1.18 +/- 0.13 and 1.03 +/- 0.10 microg/ml, tmax 5.25 +/- 1.03 and 7.48 +/- 1.09 h and AUC12h 8.64 +/- 1.19 and 8.27 +/- 0.85 microg x h/ml were obtained.",The influence of malnutrition on the oral pharmacokinetics of nimesulide in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19544676/),[μg] / [ml],1.18,59926,DB04743,Nimesulide
,19544676,Cmax,"Nimesulide whole blood levels were determined by HPLC and the pharmacokinetic parameters; Cmax 1.18 +/- 0.13 and 1.03 +/- 0.10 microg/ml, tmax 5.25 +/- 1.03 and 7.48 +/- 1.09 h and AUC12h 8.64 +/- 1.19 and 8.27 +/- 0.85 microg x h/ml were obtained.",The influence of malnutrition on the oral pharmacokinetics of nimesulide in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19544676/),[μg] / [ml],1.03,59927,DB04743,Nimesulide
,19544676,tmax,"Nimesulide whole blood levels were determined by HPLC and the pharmacokinetic parameters; Cmax 1.18 +/- 0.13 and 1.03 +/- 0.10 microg/ml, tmax 5.25 +/- 1.03 and 7.48 +/- 1.09 h and AUC12h 8.64 +/- 1.19 and 8.27 +/- 0.85 microg x h/ml were obtained.",The influence of malnutrition on the oral pharmacokinetics of nimesulide in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19544676/),h,5.25,59928,DB04743,Nimesulide
,19544676,tmax,"Nimesulide whole blood levels were determined by HPLC and the pharmacokinetic parameters; Cmax 1.18 +/- 0.13 and 1.03 +/- 0.10 microg/ml, tmax 5.25 +/- 1.03 and 7.48 +/- 1.09 h and AUC12h 8.64 +/- 1.19 and 8.27 +/- 0.85 microg x h/ml were obtained.",The influence of malnutrition on the oral pharmacokinetics of nimesulide in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19544676/),h,7.48,59929,DB04743,Nimesulide
,19544676,AUC12h,"Nimesulide whole blood levels were determined by HPLC and the pharmacokinetic parameters; Cmax 1.18 +/- 0.13 and 1.03 +/- 0.10 microg/ml, tmax 5.25 +/- 1.03 and 7.48 +/- 1.09 h and AUC12h 8.64 +/- 1.19 and 8.27 +/- 0.85 microg x h/ml were obtained.",The influence of malnutrition on the oral pharmacokinetics of nimesulide in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19544676/),[h·μg] / [ml],8.64,59930,DB04743,Nimesulide
,19544676,AUC12h,"Nimesulide whole blood levels were determined by HPLC and the pharmacokinetic parameters; Cmax 1.18 +/- 0.13 and 1.03 +/- 0.10 microg/ml, tmax 5.25 +/- 1.03 and 7.48 +/- 1.09 h and AUC12h 8.64 +/- 1.19 and 8.27 +/- 0.85 microg x h/ml were obtained.",The influence of malnutrition on the oral pharmacokinetics of nimesulide in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19544676/),[h·μg] / [ml],8.27,59931,DB04743,Nimesulide
,22213194,extraction efficiency,"With a simple liquid-liquid extraction procedure using the mixture of methyl tert-butyl ether-hexane (1:2, v/v), the mean extraction efficiency of JCC76 in rat plasma was determined as 89.5-97.3% and no obvious matrix effect was observed.","Development and validation of a rapid LC-MS/MS method for the determination of JCC76, a novel antitumor agent for breast cancer, in rat plasma and its application to a pharmacokinetics study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22213194/),%,89.5-97.3,60530,DB04743,Nimesulide
,16800099,Synovia,"Synovia and plasma nimesulide concentrations were 19.7 +/- 8.6, 11.8 +/- 3.0 and 1958.8 +/- 397.5, 3631.9 +/- 799.3 ng/ ml for topical and oral administration groups, respectively.",The diffusion of nimesulide gel into synovial fluid: a comparison between administration routes. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16800099/),[ng] / [ml],19.7,66782,DB04743,Nimesulide
,16800099,Synovia,"Synovia and plasma nimesulide concentrations were 19.7 +/- 8.6, 11.8 +/- 3.0 and 1958.8 +/- 397.5, 3631.9 +/- 799.3 ng/ ml for topical and oral administration groups, respectively.",The diffusion of nimesulide gel into synovial fluid: a comparison between administration routes. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16800099/),[ng] / [ml],11.8,66783,DB04743,Nimesulide
,16800099,Synovia,"Synovia and plasma nimesulide concentrations were 19.7 +/- 8.6, 11.8 +/- 3.0 and 1958.8 +/- 397.5, 3631.9 +/- 799.3 ng/ ml for topical and oral administration groups, respectively.",The diffusion of nimesulide gel into synovial fluid: a comparison between administration routes. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16800099/),[ng] / [ml],1958.8,66784,DB04743,Nimesulide
,16800099,Synovia,"Synovia and plasma nimesulide concentrations were 19.7 +/- 8.6, 11.8 +/- 3.0 and 1958.8 +/- 397.5, 3631.9 +/- 799.3 ng/ ml for topical and oral administration groups, respectively.",The diffusion of nimesulide gel into synovial fluid: a comparison between administration routes. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16800099/),[ng] / [ml],3631.9,66785,DB04743,Nimesulide
,16800099,concentrations,"Synovia and plasma nimesulide concentrations were 19.7 +/- 8.6, 11.8 +/- 3.0 and 1958.8 +/- 397.5, 3631.9 +/- 799.3 ng/ ml for topical and oral administration groups, respectively.",The diffusion of nimesulide gel into synovial fluid: a comparison between administration routes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16800099/),[ng] / [ml],11.8,66786,DB04743,Nimesulide
,16800099,concentrations,"Synovia and plasma nimesulide concentrations were 19.7 +/- 8.6, 11.8 +/- 3.0 and 1958.8 +/- 397.5, 3631.9 +/- 799.3 ng/ ml for topical and oral administration groups, respectively.",The diffusion of nimesulide gel into synovial fluid: a comparison between administration routes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16800099/),[ng] / [ml],1958.8,66787,DB04743,Nimesulide
,16800099,concentrations,"Synovia and plasma nimesulide concentrations were 19.7 +/- 8.6, 11.8 +/- 3.0 and 1958.8 +/- 397.5, 3631.9 +/- 799.3 ng/ ml for topical and oral administration groups, respectively.",The diffusion of nimesulide gel into synovial fluid: a comparison between administration routes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16800099/),[ng] / [ml],3631.9,66788,DB04743,Nimesulide
,19544678,Cmax,"Pharmacokinetic parameters obtained were as follows: Cmax 1.18 +/- 0.16 and 1.93 +/- 0.12 microg/ml, tmax 5.25 +/- 1.03 and 3.21 +/- 0.91 h and AUC 8.65 +/- 1.19 and 13.74 +/- 0.70 microg hr/ml for carboxy-methylcellulose and Eskaflam, respectively.",Comparison of suspension composition on the pharmacokinetics of nimesulide in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19544678/),[μg] / [ml],1.18,71919,DB04743,Nimesulide
,19544678,Cmax,"Pharmacokinetic parameters obtained were as follows: Cmax 1.18 +/- 0.16 and 1.93 +/- 0.12 microg/ml, tmax 5.25 +/- 1.03 and 3.21 +/- 0.91 h and AUC 8.65 +/- 1.19 and 13.74 +/- 0.70 microg hr/ml for carboxy-methylcellulose and Eskaflam, respectively.",Comparison of suspension composition on the pharmacokinetics of nimesulide in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19544678/),[μg] / [ml],1.93,71920,DB04743,Nimesulide
,19544678,tmax,"Pharmacokinetic parameters obtained were as follows: Cmax 1.18 +/- 0.16 and 1.93 +/- 0.12 microg/ml, tmax 5.25 +/- 1.03 and 3.21 +/- 0.91 h and AUC 8.65 +/- 1.19 and 13.74 +/- 0.70 microg hr/ml for carboxy-methylcellulose and Eskaflam, respectively.",Comparison of suspension composition on the pharmacokinetics of nimesulide in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19544678/),h,5.25,71921,DB04743,Nimesulide
,19544678,tmax,"Pharmacokinetic parameters obtained were as follows: Cmax 1.18 +/- 0.16 and 1.93 +/- 0.12 microg/ml, tmax 5.25 +/- 1.03 and 3.21 +/- 0.91 h and AUC 8.65 +/- 1.19 and 13.74 +/- 0.70 microg hr/ml for carboxy-methylcellulose and Eskaflam, respectively.",Comparison of suspension composition on the pharmacokinetics of nimesulide in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19544678/),h,3.21,71922,DB04743,Nimesulide
,19544678,AUC,"Pharmacokinetic parameters obtained were as follows: Cmax 1.18 +/- 0.16 and 1.93 +/- 0.12 microg/ml, tmax 5.25 +/- 1.03 and 3.21 +/- 0.91 h and AUC 8.65 +/- 1.19 and 13.74 +/- 0.70 microg hr/ml for carboxy-methylcellulose and Eskaflam, respectively.",Comparison of suspension composition on the pharmacokinetics of nimesulide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19544678/),[h·μg] / [ml],8.65,71923,DB04743,Nimesulide
,19544678,AUC,"Pharmacokinetic parameters obtained were as follows: Cmax 1.18 +/- 0.16 and 1.93 +/- 0.12 microg/ml, tmax 5.25 +/- 1.03 and 3.21 +/- 0.91 h and AUC 8.65 +/- 1.19 and 13.74 +/- 0.70 microg hr/ml for carboxy-methylcellulose and Eskaflam, respectively.",Comparison of suspension composition on the pharmacokinetics of nimesulide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19544678/),[h·μg] / [ml],13.74,71924,DB04743,Nimesulide
,22451531,maximal concentration (C(max)),"After oral dose of 100 mg nimesulide to western subjects, a mean maximal concentration (C(max)) of 2.86 ∼ 6.5 µg/mL was reached at 1.22 ∼ 2.75 h and mean t(1/2β) of 1.8 ∼ 4.74 h.",Quantification of nimesulide in human plasma by high-performance liquid chromatography with ultraviolet detector (HPLC-UV): application to pharmacokinetic studies in 28 healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451531/),[μg] / [ml],2.86,81934,DB04743,Nimesulide
,22451531,t(1/2β),"After oral dose of 100 mg nimesulide to western subjects, a mean maximal concentration (C(max)) of 2.86 ∼ 6.5 µg/mL was reached at 1.22 ∼ 2.75 h and mean t(1/2β) of 1.8 ∼ 4.74 h.",Quantification of nimesulide in human plasma by high-performance liquid chromatography with ultraviolet detector (HPLC-UV): application to pharmacokinetic studies in 28 healthy Korean subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451531/),∼,1.8,81935,DB04743,Nimesulide
,22451531,AUC(0-infinity),"Several pharmacokinetic parameters were represented: AUC(0-infinity) = 113.0 mg-h/mL, C(max) = 12.06 mg/mL, time for maximal concentrations (T(max)) = 3.19 h and t(1/2β) = 4.51 h.",Quantification of nimesulide in human plasma by high-performance liquid chromatography with ultraviolet detector (HPLC-UV): application to pharmacokinetic studies in 28 healthy Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451531/),[mg-h] / [ml],113.0,81936,DB04743,Nimesulide
,22451531,C(max),"Several pharmacokinetic parameters were represented: AUC(0-infinity) = 113.0 mg-h/mL, C(max) = 12.06 mg/mL, time for maximal concentrations (T(max)) = 3.19 h and t(1/2β) = 4.51 h.",Quantification of nimesulide in human plasma by high-performance liquid chromatography with ultraviolet detector (HPLC-UV): application to pharmacokinetic studies in 28 healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451531/),[mg] / [ml],12.06,81937,DB04743,Nimesulide
,22451531,time for maximal concentrations (T(max)),"Several pharmacokinetic parameters were represented: AUC(0-infinity) = 113.0 mg-h/mL, C(max) = 12.06 mg/mL, time for maximal concentrations (T(max)) = 3.19 h and t(1/2β) = 4.51 h.",Quantification of nimesulide in human plasma by high-performance liquid chromatography with ultraviolet detector (HPLC-UV): application to pharmacokinetic studies in 28 healthy Korean subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451531/),h,3.19,81938,DB04743,Nimesulide
,22451531,t(1/2β),"Several pharmacokinetic parameters were represented: AUC(0-infinity) = 113.0 mg-h/mL, C(max) = 12.06 mg/mL, time for maximal concentrations (T(max)) = 3.19 h and t(1/2β) = 4.51 h.",Quantification of nimesulide in human plasma by high-performance liquid chromatography with ultraviolet detector (HPLC-UV): application to pharmacokinetic studies in 28 healthy Korean subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451531/),h,4.51,81939,DB04743,Nimesulide
,16013036,flow rate,The chromatographic separation was achieved by gradient elution consisting of 0.05 M formic acid (pH 3)-acetonitrile-methanol-water at a flow rate of 1.0 mL/min.,"Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),[ml] / [min],1.0,105998,DB04743,Nimesulide
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,15.63,105999,DB04743,Nimesulide
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,17.20,106000,DB04743,Nimesulide
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,21.66,106001,DB04743,Nimesulide
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,24.95,106002,DB04743,Nimesulide
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,26.27,106003,DB04743,Nimesulide
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,30.24,106004,DB04743,Nimesulide
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,32.22,106005,DB04743,Nimesulide
>,16013036,Absolute recovery,Absolute recovery was >83% from human plasma for all the analytes and IS.,"Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),%,83,106006,DB04743,Nimesulide
,2227079,peak plasma concentration,"Absorption of nimesulide was relatively fast, a peak plasma concentration of 75 mg/l being reached 3 h after administration, and the elimination half-life was 3.15 h.",Pharmacokinetics and therapeutic study with nimesulide suppositories in children with post-operative pain and inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2227079/),[mg] / [l],75,120352,DB04743,Nimesulide
,2227079,elimination half-life,"Absorption of nimesulide was relatively fast, a peak plasma concentration of 75 mg/l being reached 3 h after administration, and the elimination half-life was 3.15 h.",Pharmacokinetics and therapeutic study with nimesulide suppositories in children with post-operative pain and inflammation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2227079/),h,3.15,120353,DB04743,Nimesulide
,9379354,recovery,The recovery of the method was 97.10 +/- 2.22%.,"High-performance thin-layer chromatography for the determination of nimesulide in human plasma, and its use in pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9379354/),%,97.10,128527,DB04743,Nimesulide
,28762846,inhibition rates,"The results indicated that after incorporating into CMS, the therapeutic effects of NMS were obviously improved, and the inhibition rates of 1:3 NMS/CMS in all pharmacodynamics tests varied from 102.2% to 904.3%.",Biomimetic synthesis of proline-derivative templated mesoporous silica for increasing the brain distribution of diazepam and improving the pharmacodynamics of nimesulide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762846/),%,102.2,140527,DB04743,Nimesulide
,28762846,inhibition rates,"The results indicated that after incorporating into CMS, the therapeutic effects of NMS were obviously improved, and the inhibition rates of 1:3 NMS/CMS in all pharmacodynamics tests varied from 102.2% to 904.3%.",Biomimetic synthesis of proline-derivative templated mesoporous silica for increasing the brain distribution of diazepam and improving the pharmacodynamics of nimesulide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762846/),%,904.3,140528,DB04743,Nimesulide
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,128.8,153272,DB04743,Nimesulide
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,48.5,153273,DB04743,Nimesulide
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,29.2,153274,DB04743,Nimesulide
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,17.,153275,DB04743,Nimesulide
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,7,153276,DB04743,Nimesulide
,11754119,run time,The chromatographic run time was 4.5 min and the weighted (1/x) calibration curve was linear in the range 10.0-2000 ng x ml(-1).,Quantification of nimesulide in human plasma by high-performance liquid chromatography/tandem mass spectrometry. Application to bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11754119/),min,4.5,156642,DB04743,Nimesulide
,7506175,maximum nimesulide plasma concentration,"A mean maximum nimesulide plasma concentration of 3.5 mg/L was achieved within 2 hours of administration, which subsequently declined over the following 12 hours.",Clinical and pharmacokinetic study of nimesulide in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506175/),[mg] / [l],3.5,162326,DB04743,Nimesulide
,7506196,peak plasma concentrations,Mean peak plasma concentrations of 2.86 to 4.58 mg/L were achieved within 1.22 to 3.83 hours of administration.,The pharmacokinetic profile of nimesulide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506196/),[mg] / [l],2.86 to 4.58,162932,DB04743,Nimesulide
,7506196,bioavailability,"When administered in suppository form, nimesulide peak plasma concentrations were lower and occurred later than those achieved after oral administration; the bioavailability of nimesulide given by suppository ranged from 54 to 96%, relative to that of orally administered formulations.",The pharmacokinetic profile of nimesulide in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506196/),%,54 to 96,162933,DB04743,Nimesulide
,7506196,volume of distribution,"Nimesulide is rapidly distributed, principally throughout the extracellular fluid compartment; values for volume of distribution ranged from 0.19 to 0.39 L/kg.",The pharmacokinetic profile of nimesulide in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506196/),[l] / [kg],0.19 to 0.39,162934,DB04743,Nimesulide
,7506196,unbound fraction,"Nimesulide is extensively bound to plasma proteins: at concentrations ranging from 0.5 to 10 mg/L, the unbound fraction varied between 0.7 and 4.0%.",The pharmacokinetic profile of nimesulide in healthy volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506196/),%,0.7 and 4.0,162935,DB04743,Nimesulide
,7506196,terminal half-life,The estimated mean terminal half-life for nimesulide varied from 1.96 to 4.73 hours.,The pharmacokinetic profile of nimesulide in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506196/),h,1.96 to 4.73,162936,DB04743,Nimesulide
,7506196,Total plasma clearance,"Total plasma clearance of nimesulide was 39.7 to 90.9 ml/h/kg, reflecting almost exclusive metabolic clearance.",The pharmacokinetic profile of nimesulide in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506196/),[ml] / [h·kg],39.7 to 90.9,162937,DB04743,Nimesulide
,7506196,extraction ratio,"The drug has a low extraction ratio, close to 0.1.",The pharmacokinetic profile of nimesulide in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506196/),,0.1,162938,DB04743,Nimesulide
,7506196,Rmin,"With oral nimesulide 100mg twice daily, only modest accumulation of nimesulide and its 4'-hydroxy derivative occurs (Rmin, 1.59 for nimesulide and 1.46 for the hydroxylated metabolite).",The pharmacokinetic profile of nimesulide in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506196/),,1.59,162939,DB04743,Nimesulide
,7506196,Rmin,"With oral nimesulide 100mg twice daily, only modest accumulation of nimesulide and its 4'-hydroxy derivative occurs (Rmin, 1.59 for nimesulide and 1.46 for the hydroxylated metabolite).",The pharmacokinetic profile of nimesulide in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506196/),,1.46,162940,DB04743,Nimesulide
,9532613,Cmax,"A peak analgesic effect was observed between 60 and 120 min, while Cmax (10.6 +/- 3.8 micrograms/ml) of nimesulide was reached at 60 min (Tmax).",Comparative analgesic activity of nimesulide and diclofenac by intramuscular route: correlation with pharmacokinetic profile of nimesulide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9532613/),[μg] / [ml],10.6,165992,DB04743,Nimesulide
,9532613,T,"A peak analgesic effect was observed between 60 and 120 min, while Cmax (10.6 +/- 3.8 micrograms/ml) of nimesulide was reached at 60 min (Tmax).",Comparative analgesic activity of nimesulide and diclofenac by intramuscular route: correlation with pharmacokinetic profile of nimesulide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9532613/),min,60,165993,DB04743,Nimesulide
,29624254,LOD,"In plasma LOQ was 0.01 ± 0.012 μg/mL, LOD was 0.001 μg/mL and linearity was observed from 10 to 0.001 pg/mL.","PHARMACOKINETICS AND BIOEQUIVALENCE STUDIES OF TWO NIMESULIDE 100 mg TABLETS: UNIT DOSE, RANDOMIZED-SEQUENCE, TWO-WAY CROSSOVER STUDY IN HEALTHY VOLUNTEERS OF PAKISTANI POPULATION. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29624254/),,0,172633,DB04743,Nimesulide
,29624254,AUC,"The average values of AUC,, was found to be 23.654 ± 0.688 and 23.532 ± 0.662 mg/L x h while C.. values were 6.101 ± 0.403 and 6.072 ± 0.403 pg/mL, respectively.","PHARMACOKINETICS AND BIOEQUIVALENCE STUDIES OF TWO NIMESULIDE 100 mg TABLETS: UNIT DOSE, RANDOMIZED-SEQUENCE, TWO-WAY CROSSOVER STUDY IN HEALTHY VOLUNTEERS OF PAKISTANI POPULATION. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29624254/),[mg] / [h·l],23.654,172634,DB04743,Nimesulide
,29624254,AUC,"The average values of AUC,, was found to be 23.654 ± 0.688 and 23.532 ± 0.662 mg/L x h while C.. values were 6.101 ± 0.403 and 6.072 ± 0.403 pg/mL, respectively.","PHARMACOKINETICS AND BIOEQUIVALENCE STUDIES OF TWO NIMESULIDE 100 mg TABLETS: UNIT DOSE, RANDOMIZED-SEQUENCE, TWO-WAY CROSSOVER STUDY IN HEALTHY VOLUNTEERS OF PAKISTANI POPULATION. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29624254/),[mg] / [h·l],23.532,172635,DB04743,Nimesulide
,29624254,C..,"The average values of AUC,, was found to be 23.654 ± 0.688 and 23.532 ± 0.662 mg/L x h while C.. values were 6.101 ± 0.403 and 6.072 ± 0.403 pg/mL, respectively.","PHARMACOKINETICS AND BIOEQUIVALENCE STUDIES OF TWO NIMESULIDE 100 mg TABLETS: UNIT DOSE, RANDOMIZED-SEQUENCE, TWO-WAY CROSSOVER STUDY IN HEALTHY VOLUNTEERS OF PAKISTANI POPULATION. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29624254/),[pg] / [ml],6.101,172636,DB04743,Nimesulide
,29624254,C..,"The average values of AUC,, was found to be 23.654 ± 0.688 and 23.532 ± 0.662 mg/L x h while C.. values were 6.101 ± 0.403 and 6.072 ± 0.403 pg/mL, respectively.","PHARMACOKINETICS AND BIOEQUIVALENCE STUDIES OF TWO NIMESULIDE 100 mg TABLETS: UNIT DOSE, RANDOMIZED-SEQUENCE, TWO-WAY CROSSOVER STUDY IN HEALTHY VOLUNTEERS OF PAKISTANI POPULATION. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29624254/),[pg] / [ml],6.072,172637,DB04743,Nimesulide
,29624254,clearance,"Mean clearance and volume of distribution of reference formulation were 64.062 ± 3.086 mL/h/kg and 9.416 ± 4.767 L, respectively.","PHARMACOKINETICS AND BIOEQUIVALENCE STUDIES OF TWO NIMESULIDE 100 mg TABLETS: UNIT DOSE, RANDOMIZED-SEQUENCE, TWO-WAY CROSSOVER STUDY IN HEALTHY VOLUNTEERS OF PAKISTANI POPULATION. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29624254/),[ml] / [h·kg],64.062,172638,DB04743,Nimesulide
,29624254,volume of distribution,"Mean clearance and volume of distribution of reference formulation were 64.062 ± 3.086 mL/h/kg and 9.416 ± 4.767 L, respectively.","PHARMACOKINETICS AND BIOEQUIVALENCE STUDIES OF TWO NIMESULIDE 100 mg TABLETS: UNIT DOSE, RANDOMIZED-SEQUENCE, TWO-WAY CROSSOVER STUDY IN HEALTHY VOLUNTEERS OF PAKISTANI POPULATION. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29624254/),l,9.416,172639,DB04743,Nimesulide
,29624254,disposition rate constant,The disposition rate constant in reference formulation was 0.339 ± 0.598 h' while in immediate release it was 0.467 ± 0.481 h-'.,"PHARMACOKINETICS AND BIOEQUIVALENCE STUDIES OF TWO NIMESULIDE 100 mg TABLETS: UNIT DOSE, RANDOMIZED-SEQUENCE, TWO-WAY CROSSOVER STUDY IN HEALTHY VOLUNTEERS OF PAKISTANI POPULATION. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29624254/),h',0.339,172640,DB04743,Nimesulide
,29624254,disposition rate constant,The disposition rate constant in reference formulation was 0.339 ± 0.598 h' while in immediate release it was 0.467 ± 0.481 h-'.,"PHARMACOKINETICS AND BIOEQUIVALENCE STUDIES OF TWO NIMESULIDE 100 mg TABLETS: UNIT DOSE, RANDOMIZED-SEQUENCE, TWO-WAY CROSSOVER STUDY IN HEALTHY VOLUNTEERS OF PAKISTANI POPULATION. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29624254/),h-',0.467,172641,DB04743,Nimesulide
,29624254,Absorption rate constant,"Absorption rate constant and distribution rate constant for reference brand were 1.409 ± 0.251 h- and 1.201 ± 0.283 h' while in immediate release formulation these values were 1.420 ± 0.214 h-' and 1.227 ± 0.263 h', respectively.","PHARMACOKINETICS AND BIOEQUIVALENCE STUDIES OF TWO NIMESULIDE 100 mg TABLETS: UNIT DOSE, RANDOMIZED-SEQUENCE, TWO-WAY CROSSOVER STUDY IN HEALTHY VOLUNTEERS OF PAKISTANI POPULATION. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29624254/),h-,1.409,172642,DB04743,Nimesulide
,29624254,Absorption rate constant,"Absorption rate constant and distribution rate constant for reference brand were 1.409 ± 0.251 h- and 1.201 ± 0.283 h' while in immediate release formulation these values were 1.420 ± 0.214 h-' and 1.227 ± 0.263 h', respectively.","PHARMACOKINETICS AND BIOEQUIVALENCE STUDIES OF TWO NIMESULIDE 100 mg TABLETS: UNIT DOSE, RANDOMIZED-SEQUENCE, TWO-WAY CROSSOVER STUDY IN HEALTHY VOLUNTEERS OF PAKISTANI POPULATION. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29624254/),h-',1.420,172643,DB04743,Nimesulide
,29624254,distribution rate constant,"Absorption rate constant and distribution rate constant for reference brand were 1.409 ± 0.251 h- and 1.201 ± 0.283 h' while in immediate release formulation these values were 1.420 ± 0.214 h-' and 1.227 ± 0.263 h', respectively.","PHARMACOKINETICS AND BIOEQUIVALENCE STUDIES OF TWO NIMESULIDE 100 mg TABLETS: UNIT DOSE, RANDOMIZED-SEQUENCE, TWO-WAY CROSSOVER STUDY IN HEALTHY VOLUNTEERS OF PAKISTANI POPULATION. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29624254/),h',1.201,172644,DB04743,Nimesulide
,29624254,distribution rate constant,"Absorption rate constant and distribution rate constant for reference brand were 1.409 ± 0.251 h- and 1.201 ± 0.283 h' while in immediate release formulation these values were 1.420 ± 0.214 h-' and 1.227 ± 0.263 h', respectively.","PHARMACOKINETICS AND BIOEQUIVALENCE STUDIES OF TWO NIMESULIDE 100 mg TABLETS: UNIT DOSE, RANDOMIZED-SEQUENCE, TWO-WAY CROSSOVER STUDY IN HEALTHY VOLUNTEERS OF PAKISTANI POPULATION. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29624254/),h',1.227,172645,DB04743,Nimesulide
,17348902,half-lives during the distribution phase (t1/2alpha),The half-lives during the distribution phase (t1/2alpha) and terminal elimination phase (t1/2beta) were 0.11+/-0.10 and 7.99+/-2.23 h respectively.,Pharmacokinetics and bioavailability of nimesulide in goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348902/),h,0.11,189255,DB04743,Nimesulide
,17348902,terminal elimination phase (t1/2beta),The half-lives during the distribution phase (t1/2alpha) and terminal elimination phase (t1/2beta) were 0.11+/-0.10 and 7.99+/-2.23 h respectively.,Pharmacokinetics and bioavailability of nimesulide in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348902/),h,7.99,189256,DB04743,Nimesulide
,17348902,steady-state volume of distribution (Vd(ss)),"The steady-state volume of distribution (Vd(ss)), total body clearance (ClB) and mean residence time (MRT) of nimesulide were 0.64+/-0.13 L/kg, 0.06+/-0.02 L/h/kg and 11.72+/-3.42 h respectively.",Pharmacokinetics and bioavailability of nimesulide in goats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348902/),[l] / [kg],0.64,189257,DB04743,Nimesulide
,17348902,total body clearance (ClB),"The steady-state volume of distribution (Vd(ss)), total body clearance (ClB) and mean residence time (MRT) of nimesulide were 0.64+/-0.13 L/kg, 0.06+/-0.02 L/h/kg and 11.72+/-3.42 h respectively.",Pharmacokinetics and bioavailability of nimesulide in goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348902/),[l] / [h·kg],0.06,189258,DB04743,Nimesulide
,17348902,mean residence time (MRT),"The steady-state volume of distribution (Vd(ss)), total body clearance (ClB) and mean residence time (MRT) of nimesulide were 0.64+/-0.13 L/kg, 0.06+/-0.02 L/h/kg and 11.72+/-3.42 h respectively.",Pharmacokinetics and bioavailability of nimesulide in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348902/),h,11.72,189259,DB04743,Nimesulide
,17348902,maximum plasma concentration (Cmax),"After i.m. administration, maximum plasma concentration (Cmax) of nimesulide was 2.83+/-1.11 microg/mL attained at 3.6+/-0.89 h (tmax).",Pharmacokinetics and bioavailability of nimesulide in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348902/),[μg] / [ml],2.83,189260,DB04743,Nimesulide
,17348902,tmax,"After i.m. administration, maximum plasma concentration (Cmax) of nimesulide was 2.83+/-1.11 microg/mL attained at 3.6+/-0.89 h (tmax).",Pharmacokinetics and bioavailability of nimesulide in goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348902/),h,3.6,189261,DB04743,Nimesulide
,17348902,bioavailability,The bioavailability of nimesulide was 68.25% after i.m. administration at 4 mg/kg BW.,Pharmacokinetics and bioavailability of nimesulide in goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348902/),%,68.25,189262,DB04743,Nimesulide
,21111692,flow rate,"Analyses were performed on an Agilent LC-MS/MS system using a Chromolith rod™ and isocratic elution with acetonitrile:10 mM ammonium acetate buffer (pH 3.5) (80:20, v/v) at a flow rate of 0.8 ml/min with a total run time of 3 min and an overall recovery of 77.15%.",Pharmacokinetic applicability of a validated liquid chromatography tandem mass spectroscopy method for orally administered curcumin loaded solid lipid nanoparticles to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21111692/),[ml] / [min],0.8,196891,DB04743,Nimesulide
,21111692,total run time,"Analyses were performed on an Agilent LC-MS/MS system using a Chromolith rod™ and isocratic elution with acetonitrile:10 mM ammonium acetate buffer (pH 3.5) (80:20, v/v) at a flow rate of 0.8 ml/min with a total run time of 3 min and an overall recovery of 77.15%.",Pharmacokinetic applicability of a validated liquid chromatography tandem mass spectroscopy method for orally administered curcumin loaded solid lipid nanoparticles to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21111692/),min,3,196892,DB04743,Nimesulide
,21111692,overall recovery,"Analyses were performed on an Agilent LC-MS/MS system using a Chromolith rod™ and isocratic elution with acetonitrile:10 mM ammonium acetate buffer (pH 3.5) (80:20, v/v) at a flow rate of 0.8 ml/min with a total run time of 3 min and an overall recovery of 77.15%.",Pharmacokinetic applicability of a validated liquid chromatography tandem mass spectroscopy method for orally administered curcumin loaded solid lipid nanoparticles to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21111692/),%,77.15,196893,DB04743,Nimesulide
,21111692,m/,Multiple reaction monitoring was used to monitor the transition for curcumin (m/z; 367/217 [M-H](-)) and IS (m/z; 307/229).,Pharmacokinetic applicability of a validated liquid chromatography tandem mass spectroscopy method for orally administered curcumin loaded solid lipid nanoparticles to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21111692/),,367,196894,DB04743,Nimesulide
,21111692,m/z,Multiple reaction monitoring was used to monitor the transition for curcumin (m/z; 367/217 [M-H](-)) and IS (m/z; 307/229).,Pharmacokinetic applicability of a validated liquid chromatography tandem mass spectroscopy method for orally administered curcumin loaded solid lipid nanoparticles to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21111692/),,307,196895,DB04743,Nimesulide
,22397600,C(max),"The C(max), t(max), mean residence time (MRT), and area under the curve from 0 to 36 h were 10.8 ± 4.2 μg/mL, 2.3 ± 1.0 h, 6.7 ± 2.1 h, 81.5 ± 26.7 μg·h/mL for the bilayer tablets and 14.8 ± 5.8 μg/mL, 2.7 ± 0.8 h, 5.6 ± 0.9 h, 95.4 ± 44.2 μg·h/mL for the dispersible tablets.",Comparison of pharmacokinetics in beagle dogs of nimesulide bilayer tablets with dispersible tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22397600/),[μg] / [ml],10.8,200250,DB04743,Nimesulide
,22397600,t(max),"The C(max), t(max), mean residence time (MRT), and area under the curve from 0 to 36 h were 10.8 ± 4.2 μg/mL, 2.3 ± 1.0 h, 6.7 ± 2.1 h, 81.5 ± 26.7 μg·h/mL for the bilayer tablets and 14.8 ± 5.8 μg/mL, 2.7 ± 0.8 h, 5.6 ± 0.9 h, 95.4 ± 44.2 μg·h/mL for the dispersible tablets.",Comparison of pharmacokinetics in beagle dogs of nimesulide bilayer tablets with dispersible tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22397600/),h,2.3,200251,DB04743,Nimesulide
,22397600,mean residence time (MRT),"The C(max), t(max), mean residence time (MRT), and area under the curve from 0 to 36 h were 10.8 ± 4.2 μg/mL, 2.3 ± 1.0 h, 6.7 ± 2.1 h, 81.5 ± 26.7 μg·h/mL for the bilayer tablets and 14.8 ± 5.8 μg/mL, 2.7 ± 0.8 h, 5.6 ± 0.9 h, 95.4 ± 44.2 μg·h/mL for the dispersible tablets.",Comparison of pharmacokinetics in beagle dogs of nimesulide bilayer tablets with dispersible tablets. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22397600/),h,2.3,200252,DB04743,Nimesulide
,22397600,area under the curve from 0 to 36 h,"The C(max), t(max), mean residence time (MRT), and area under the curve from 0 to 36 h were 10.8 ± 4.2 μg/mL, 2.3 ± 1.0 h, 6.7 ± 2.1 h, 81.5 ± 26.7 μg·h/mL for the bilayer tablets and 14.8 ± 5.8 μg/mL, 2.7 ± 0.8 h, 5.6 ± 0.9 h, 95.4 ± 44.2 μg·h/mL for the dispersible tablets.",Comparison of pharmacokinetics in beagle dogs of nimesulide bilayer tablets with dispersible tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22397600/),[h·μg] / [ml],81.5,200253,DB04743,Nimesulide
,22397600,area under the curve from 0 to 36 h,"The C(max), t(max), mean residence time (MRT), and area under the curve from 0 to 36 h were 10.8 ± 4.2 μg/mL, 2.3 ± 1.0 h, 6.7 ± 2.1 h, 81.5 ± 26.7 μg·h/mL for the bilayer tablets and 14.8 ± 5.8 μg/mL, 2.7 ± 0.8 h, 5.6 ± 0.9 h, 95.4 ± 44.2 μg·h/mL for the dispersible tablets.",Comparison of pharmacokinetics in beagle dogs of nimesulide bilayer tablets with dispersible tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22397600/),[h·μg] / [ml],95.4,200254,DB04743,Nimesulide
,27284972,run time,"Prepared plasma samples were analyzed under the same LC-MS/MS conditions, and chromatographic separation was realized by using an Ultimate C18 column, with run time being 5min for each sample.",Simultaneous determination of nimesulide and its four possible metabolites in human plasma by LC-MS/MS and its application in a study of pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27284972/),min,5,237094,DB04743,Nimesulide
,22119125,IC(50)s,Some of them displayed very potent anti-cancer activity with IC(50)s around 100 nM-200 nM to inhibit SKBR-3 breast cancer cell growth.,"From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22119125/),nM,100,241004,DB04743,Nimesulide
,22119125,IC(50)s,Some of them displayed very potent anti-cancer activity with IC(50)s around 100 nM-200 nM to inhibit SKBR-3 breast cancer cell growth.,"From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22119125/),nM,200,241005,DB04743,Nimesulide
,22119125,IC(50)s,CSUOH0901 (NSC751382) from the compound library also inhibits the growth of the 60 cancer cell lines used at National Cancer Institute Developmental therapeutics Program (NCIDTP) with IC(50)s around 100 nM-500 nM.,"From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22119125/),nM,100,241006,DB04743,Nimesulide
,22119125,IC(50)s,CSUOH0901 (NSC751382) from the compound library also inhibits the growth of the 60 cancer cell lines used at National Cancer Institute Developmental therapeutics Program (NCIDTP) with IC(50)s around 100 nM-500 nM.,"From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22119125/),nM,500,241007,DB04743,Nimesulide
,1807292,peak plasma concentrations,After the single dose of 200 mg peak plasma concentrations of the drug (9.85 micrograms/ml) were reached at 3.17 hours and the half-life during the elimination phase was 4.95 hours.,First dose and steady state pharmacokinetics of nimesulide and its 4-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807292/),[μg] / [ml],9.85,254166,DB04743,Nimesulide
,1807292,half-life during the elimination phase,After the single dose of 200 mg peak plasma concentrations of the drug (9.85 micrograms/ml) were reached at 3.17 hours and the half-life during the elimination phase was 4.95 hours.,First dose and steady state pharmacokinetics of nimesulide and its 4-hydroxy metabolite in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807292/),h,4.95,254167,DB04743,Nimesulide
,1807292,apparent half-life,The metabolite reached highest plasma levels (3.03 micrograms/ml) at 5.33 hours and its apparent half-life was similar to that of the parent drug (4.78 hours).,First dose and steady state pharmacokinetics of nimesulide and its 4-hydroxy metabolite in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807292/),h,4.78,254168,DB04743,Nimesulide
,29128828,half-life,The half-life of betamethasone was 8.5days.,Quantitative assessment of betamethasone dual-acting formulation in urine of patients with rheumatoid arthritis and ankylosing spondylitis after single-dose intramuscular administration and its application to long-term pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128828/),d,8.5,259718,DB04743,Nimesulide
,29128828,elimination rate constant,The elimination rate constant was 2.49h-1; the mean clearance was 4.72L/d.,Quantitative assessment of betamethasone dual-acting formulation in urine of patients with rheumatoid arthritis and ankylosing spondylitis after single-dose intramuscular administration and its application to long-term pharmacokinetic study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128828/),1/[h],2.49,259719,DB04743,Nimesulide
,29128828,clearance,The elimination rate constant was 2.49h-1; the mean clearance was 4.72L/d.,Quantitative assessment of betamethasone dual-acting formulation in urine of patients with rheumatoid arthritis and ankylosing spondylitis after single-dose intramuscular administration and its application to long-term pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128828/),[l] / [d],4.72,259720,DB04743,Nimesulide
